Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease

被引:28
|
作者
Horowitz, Mia [1 ]
Braunstein, Hila [1 ]
Zimran, Ari [2 ,3 ]
Revel-Vilk, Shoshana [2 ,3 ]
Goker-Alpan, Ozlem [4 ]
机构
[1] Tel Aviv Univ, Schmunis Sch Biomed & Canc Res, IL-69978 Tel Aviv, Israel
[2] Shaare Zedek Med Ctr, Gaucher Unit, Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[4] Lysosomal & Rare Disorders Res & Treatment Ctr LD, Fairfax, VA USA
关键词
Gaucher disease; Glucocerebrosidase (GCase); Parkinson disease; Misfolding; Unfolded Protein Response (UPR); UNFOLDED PROTEIN RESPONSE; SPHINGOLIPID ACTIVATOR PROTEINS; HUMAN GLUCOCEREBROSIDASE GENE; ENZYME REPLACEMENT THERAPY; ALPHA-SYNUCLEIN; ENDOPLASMIC-RETICULUM; BETA-GLUCOSIDASE; GBA MUTATIONS; RECOMBINANT GLUCOCEREBROSIDASE; SUBSTANTIA-NIGRA;
D O I
10.1016/j.addr.2022.114402
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lysosomes have a critical role in maintaining normal cellular homeostasis mediated by their involvement in secretion, plasma membrane repair, cell signaling and energy metabolism. Lysosomal storage disorders (LSDs) are a group of approximately 50 rare disorders caused by lysosomal dysfunction that occur due to mutations in a gene of a lysosomal protein. Gaucher disease (GD), an autosomal recessive disorder and one of the most common LSDs, is caused by the deficiency of the lysosomal enzyme acid-beta-glucocerebrosidase (GCase), due to biallelic mutations in the GBA1 gene. Reduced GCase activity leads to the accumulation of glucosylceramide (GlcCer), which is deacylated by lysosomal acid ceramidase to a toxic metabolite, glucosylshpingosine (GlcSph). Most GBA1 variants are recognized as misfolded in the ER, where the retention for refolding attempts initiates stress and activates the stress response known as the Unfolded Protein Response (UPR). The distinct clinical subtypes of GD are based on whether there is primary involvement of the central nervous system. Type 1 GD (GD1) is the nonneuropathic type, however, the recent recognition of the association of GD with the development of parkinsonism defies this classification. Patients with GD1 and carriers of GBA1 mutations are at risk for the development of parkinsonian manifestations. Parkinson disease (PD), the second most prevalent neurodegenerative disease, culminates in a movement disorder with the premature death of the patients. In PD and related disorders, collectively called synucleinopathies, the hallmark pathology is a-synuclein positive aggregates referred to as Lewy bodies or Lewy neurites and the death of dopaminergic neurons. While PD is mostly sporadic, in similar to 5-10% of cases, the disease results from pathogenic variants in a growing number of genes. The most common genetic cause of PD is mutations in GBA1. Two mechanisms have been proposed for this link: (A) a "gain of function" mechanism, in which mutant GCase (protein) contributes to aggregate formation and to the development of PD, and the (B) "haploinsufficiency" ("loss of function") model, suggesting that one normal GBA1 allele is insufficient to carry adequate GCase activity and functional deficiency of GCase impedes a-synuclein metabolism. Lysosomal dysfunction, compromised autophagy and mitophagy further enhance the accumulation of a-synuclein, which results in the development of PD pathology. The present review will elaborate on the biology of GD, its association with PD and related disorders, and discuss the possible mechanisms underlying this association. (c) 2022 Elsevier B.V. All rights reserved.
引用
下载
收藏
页数:16
相关论文
共 50 条
  • [1] Lysosomal Storage Disorders and Parkinson's Disease: Gaucher Disease and Beyond
    Shachar, Tamar
    Lo Bianco, Christophe
    Recchia, Alessandra
    Wiessner, Christoph
    Raas-Rothschild, Annick
    Futerman, Anthony H.
    MOVEMENT DISORDERS, 2011, 26 (09) : 1593 - 1604
  • [2] Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease
    Wong, Yvette C.
    Krainc, Dimitri
    MOVEMENT DISORDERS, 2016, 31 (11) : 1610 - 1618
  • [3] Cellular and molecular mechanisms of antioxidants in Parkinson's disease
    Jairo Sutachan, Jhon
    Casas, Zulma
    Luz Albarracin, Sonia
    Robert Stab, Bernd, II
    Samudio, Ismael
    Gonzalez, Janneth
    Morales, Ludis
    Barreto, George E.
    NUTRITIONAL NEUROSCIENCE, 2012, 15 (03) : 120 - 126
  • [4] Parkinson's disease in patients with Gaucher disease: causation or association?
    Pandey, B.
    MOVEMENT DISORDERS, 2023, 38 : S484 - S485
  • [5] Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease
    Guo, Tiantian
    Zhang, Denghong
    Zeng, Yuzhe
    Huang, Timothy Y.
    Xu, Huaxi
    Zhao, Yingjun
    MOLECULAR NEURODEGENERATION, 2020, 15 (01)
  • [6] Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
    Tiantian Guo
    Denghong Zhang
    Yuzhe Zeng
    Timothy Y. Huang
    Huaxi Xu
    Yingjun Zhao
    Molecular Neurodegeneration, 15
  • [7] Cellular and Molecular Mechanisms Underlying Tricuspid Valve Development and Disease
    Salerno, Nadia
    Panuccio, Giuseppe
    Sabatino, Jolanda
    Leo, Isabella
    Torella, Michele
    Sorrentino, Sabato
    De Rosa, Salvatore
    Torella, Daniele
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (10)
  • [8] The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson's disease
    Kinghorn, Kerri J.
    Asghari, Amir M.
    Castillo-Quan, Jorge Ivan
    NEURAL REGENERATION RESEARCH, 2017, 12 (03) : 380 - 384
  • [9] The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson's disease
    Kerri J.Kinghorn
    Amir M.Asghari
    Jorge Iván Castillo-Quan
    Neural Regeneration Research, 2017, 12 (03) : 380 - 384
  • [10] Molecular mechanisms and neuroprotection in cellular models of Parkinson's disease
    Dohm, C. P.
    Esposito, A.
    Liman, J.
    Reed, J. C.
    Wouters, F. S.
    Baehr, M. ]
    Kermer, P.
    JOURNAL OF NEURAL TRANSMISSION, 2007, 114 (03) : X - X